{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:34:32Z","timestamp":1792892072738,"version":"4.5.0"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:sec><jats:label\/><jats:p><jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold><\/jats:p><jats:p>\u2022\u2003Woohwangcheongsimwon suspension has traditionally been used for the treatment and prevention of stroke, hypertension, palpitations, convulsions and unconsciousness in various Asian countries.<\/jats:p><jats:p>\u2022\u2003Woohwangcheongsimwon suspensions showed an inhibitory effect on CYP2B6 activity<jats:italic>in vitro<\/jats:italic>. Two terpenoids, borneol and isoborneol, are major constituents of woohwangcheongsimwon suspension, and show a competitive inhibition of CYP2B6 with<jats:italic>K<\/jats:italic><jats:sub>i<\/jats:sub>values of 9.5 and 5.9\u2003\u00b5<jats:sc>m<\/jats:sc>, respectively.<\/jats:p><jats:p>\u2022\u2003Bupropion undergoes metabolic transformation to the active metabolite, 4\u2010hydroxybupropion, primarily via CYP2B6 both<jats:italic>in vivo<\/jats:italic>and<jats:italic>in vitro<\/jats:italic>. It is often used as a CYP2B6 substrate for clinical drug\u2013drug interaction studies.<\/jats:p><jats:p>\u2022\u2003Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.<\/jats:p><jats:p><jats:bold>WHAT THIS STUDY ADDS<\/jats:bold><\/jats:p><jats:p>\u2022\u2003Co\u2010administration with woohwangcheongsimwon suspension did not alter the pharmacokinetics of bupropion or its metabolite, 4\u2010hydroxybupropion.<\/jats:p><jats:p>\u2022\u2003Dosage adjustment of bupropion is unnecessary in patients concomitantly administered the highest recommended daily dose of woohwangcheongsimwon suspension.<\/jats:p><\/jats:sec><jats:sec><jats:title>AIMS<\/jats:title><jats:p>To examine the effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4\u2010hydroxybupropion, formed via CYP2B6<jats:italic>in vivo<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>A two\u2010way crossover clinical trial with a 2 week washout period was conducted in 14 healthy volunteers. In phases I and II, subjects received 150\u2003mg bupropion with or without woohwangcheongsimwon suspension four times (at \u22120.17, 3.5, 23.5 and 47.5\u2003h, with the time of bupropion administration taken as 0\u2003h) in a randomized balanced crossover order. Bupropion and 4\u2010hydroxybupropion plasma concentrations were measured for up to 72\u2003h by LC\u2010MS\/MS. Urine was collected up to 24\u2003h to calculate the renal clearance. In addition, the<jats:italic>CYP2B6<\/jats:italic>*6 genotype was also analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The geometric mean ratios and 90% confidence interval of bupropion with woohwangcheongsimwon suspension relative to bupropion alone were 0.976 (0.917, 1.04) for AUC(0,\u221e) and 0.948 (0.830,1.08) for<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>, respectively. The corresponding values for 4\u2010hydroxybupropion were 0.856 (0.802, 0.912) and 0.845 (0.782, 0.914), respectively. The<jats:italic>t<\/jats:italic><jats:sub>max<\/jats:sub>values of bupropion and 4\u2010hydroxybupropion were not significantly different between the two groups (<jats:italic>P<\/jats:italic>\u2003&gt;\u20030.05). The pharmacokinetic parameters of bupropion and 4\u2010hydroxybupropion were unaffected by woohwangcheongsimwon suspension.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>These results indicate that woohwangcheongsimwon suspension has a negligible effect on the disposition of a single dose of bupropion<jats:italic>in vivo<\/jats:italic>. As a result, temporary co\u2010administration with woohwangcheongsimwon suspension does not seem to require a dosage adjustment of bupropion.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2010.03661.x","type":"journal-article","created":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T13:07:50Z","timestamp":1267448870000},"page":"126-131","source":"Crossref","is-referenced-by-count":13,"title":["Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4\u2010hydroxybupropion, in healthy subjects"],"prefix":"10.1111","volume":"70","author":[{"given":"Hyunmi","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Kyung","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo\u2010Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eon\u2010Jeong","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho\u2010Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u2010Hong","family":"Shon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang\u2010Hyeon","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae\u2010Gook","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,11]]},"reference":[{"key":"e_1_2_7_2_2","volume-title":"Korean Pharmaceutical Codex","author":"Korea Food and Drug Administration","year":"2007"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.019612"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2008.06.003"},{"key":"e_1_2_7_5_2","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0026-895X(24)12046-9","article-title":"CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants","volume":"28","author":"Hesse LM","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_7_6_2","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0026-895X(24)12054-8","article-title":"Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity","volume":"28","author":"Faucette SR","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_7_7_2","first-page":"1123","article-title":"Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation","volume":"29","author":"Faucette SR","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.03.010"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.02.010"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00202-9"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100027"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000135479.78529.60"},{"key":"e_1_2_7_13_2","first-page":"1","article-title":"Reference values for body fat content as a measure for desirable body fat content","volume":"23","author":"Kramer HJ","year":"1984","journal-title":"Z Ernahrungswiss"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.7.7.995"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.07.007"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2003.02051.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(03)00136-9"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200310000-00005"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498250701570277"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2008.06.031"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03661.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03661.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T22:36:03Z","timestamp":1739918163000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03661.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,11]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03661.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03661.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,11]]}}}